Disease Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

Filtering

  • Case insensitive filtering will display rows where any text in any cell matches the filter term
  • Simple literal full or partial string matches
  • Separate multiple filter terms with a spaces, order doesn't matter (a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page, filtering has no impact on query parameters
  • Use quotes to match a longer phrase which contains spaces "mtor c1483f"

Sorting

  • Generally, the default sort order for tables is set to be first column ascending, however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column, be sure to set ascending or descending order for a given column, before moving on to the next column.

Molecular Profile Therapy Indication/Tumor Type Response Type Profile Response Detail
Unknown unknown Danusertib prostate cancer not applicable detail...
Unknown unknown GDC-0349 prostate cancer not applicable detail...
Unknown unknown Bicalutamide prostate cancer sensitive detail...
Unknown unknown Enzalutamide prostate cancer not applicable detail...
Unknown unknown UC-773587 prostate cancer not applicable detail...
Unknown unknown UC-857993 prostate cancer not applicable detail...
Unknown unknown Docetaxel + Everolimus prostate cancer not applicable detail...
Unknown unknown Metformin prostate cancer not applicable detail...
Unknown unknown Sapanisertib prostate cancer not applicable detail...
Unknown unknown AS605240 prostate cancer not applicable detail...
Unknown unknown TGX-221 prostate cancer not applicable detail...
PIK3CA mutant CH5132799 prostate cancer sensitive detail...
PIK3CA Q546R CH5132799 prostate cancer sensitive detail...
ATM mutant Olaparib prostate cancer sensitive detail...
Unknown unknown Olaparib prostate cancer not applicable detail...
ATM inact mut Olaparib prostate cancer sensitive detail...
Unknown unknown BI2536 + Metformin prostate cancer not applicable detail...
Unknown unknown AZD1208 prostate cancer not applicable detail...
Unknown unknown Docetaxel + MEDI5117 prostate cancer not applicable detail...
Unknown unknown Docetaxel + PF-00562271 prostate cancer not applicable detail...
Unknown unknown C6-ceramide prostate cancer not applicable detail...
Unknown unknown Carnosic acid prostate cancer not applicable detail...
Unknown unknown Forskolin prostate cancer not applicable detail...
Unknown unknown CX-6258 prostate cancer not applicable detail...
Unknown unknown JNJ-54302833 prostate cancer not applicable detail...
Unknown unknown TAK-960 prostate cancer not applicable detail...
Unknown unknown SPC3042 prostate cancer not applicable detail...
Unknown unknown Paclitaxel + SPC3042 prostate cancer not applicable detail...
Unknown unknown Bicalutamide + Everolimus prostate cancer not applicable detail...
Unknown unknown KX2-391 prostate cancer not applicable detail...
Unknown unknown AT-101 + Bicalutamide prostate cancer no benefit detail...
Unknown unknown NSC156529 prostate cancer not applicable detail...
Unknown unknown EC-70124 prostate cancer not applicable detail...
Unknown unknown Bevacizumab + Docetaxel prostate cancer no benefit detail...
Unknown unknown WANT3 prostate cancer not applicable detail...
Unknown unknown PF-00562271 prostate cancer not applicable detail...
Unknown unknown AGS-1C4D4 prostate cancer not applicable detail...
Unknown unknown AGS-PSCA prostate cancer not applicable detail...
Unknown unknown Zibotentan prostate cancer no benefit detail...
AKT1 E17K NRAS G12D BAY1125976 prostate cancer sensitive detail...
NOTCH1 positive Docetaxel + PF-03084014 prostate cancer predicted - sensitive detail...
Unknown unknown RO6839921 prostate cancer not applicable detail...
Unknown unknown AZD8186 prostate cancer not applicable detail...
Unknown unknown Niraparib prostate cancer not applicable detail...
Unknown unknown Cabozantinib + unspecified CTLA4 antibody + unspecified PD-1 antibody prostate cancer not applicable detail...
Unknown unknown Dactolisib + unspecified CTLA4 antibody + unspecified PD-1 antibody prostate cancer not applicable detail...
Unknown unknown DCBCI0901 prostate cancer not applicable detail...
Unknown unknown X480 prostate cancer not applicable detail...
Unknown unknown BGP-15 prostate cancer not applicable detail...
Unknown unknown OPB-111077 prostate cancer not applicable detail...
Unknown unknown AZD8186 + Vistusertib prostate cancer not applicable detail...
Unknown unknown Abiraterone + Prednisone + Veliparib prostate cancer not applicable detail...
Unknown unknown Apalutamide prostate cancer not applicable detail...
Unknown unknown ONC201 prostate cancer not applicable detail...
Unknown unknown Navitoclax + TAK-901 prostate cancer not applicable detail...
Unknown unknown Barasertib + Navitoclax prostate cancer not applicable detail...
Unknown unknown Capivasertib + Docetaxel + Prednisone prostate cancer not applicable detail...
Unknown unknown Relugolix prostate cancer not applicable detail...
Unknown unknown AZD3514 prostate cancer not applicable detail...
Unknown unknown AMG208 prostate cancer not applicable detail...
Unknown unknown Abiraterone + Buparlisib prostate cancer no benefit detail...
Unknown unknown Abiraterone + Dactolisib prostate cancer no benefit detail...
FANCA S1088F Olaparib prostate cancer predicted - sensitive detail...
Unknown unknown SM88 prostate cancer not applicable detail...
Unknown unknown Abiraterone + Prednisone prostate cancer not applicable detail...
Unknown unknown CC214-2 prostate cancer not applicable detail...
Unknown unknown Tisotumab Vedotin prostate cancer not applicable detail...
Unknown unknown Abiraterone + Onvansertib prostate cancer not applicable detail...
Unknown unknown Selinexor prostate cancer not applicable detail...
Unknown unknown Abiraterone + Olaparib prostate cancer not applicable detail...
Unknown unknown ABBV-744 prostate cancer not applicable detail...
Unknown unknown AB928 + Doxorubicin prostate cancer not applicable detail...
Unknown unknown AB928 + Oxaliplatin prostate cancer not applicable detail...
Unknown unknown Alisertib prostate cancer not applicable detail...
Unknown unknown Darolutamide prostate cancer not applicable detail...
Unknown unknown MC180295 prostate cancer not applicable detail...
Unknown unknown Durvalumab + Olaparib prostate cancer not applicable detail...
ATM mutant N/A prostate cancer not applicable detail...
APC inact mut Abiraterone prostate cancer decreased response detail...
APC inact mut Enzalutamide prostate cancer decreased response detail...
Unknown unknown Abiraterone + Onalespib + Prednisone prostate cancer no benefit detail...
Unknown unknown MYCi975 + unspecified PD-1 antibody prostate cancer not applicable detail...
ARID1A inact mut Olaparib prostate cancer predicted - sensitive detail...
ATRX inact mut Olaparib prostate cancer predicted - sensitive detail...
FANCA inact mut Olaparib prostate cancer predicted - sensitive detail...
ATM inact mut Rucaparib prostate cancer no benefit detail...
FANCA inact mut Rucaparib prostate cancer predicted - sensitive detail...
Unknown unknown Birabresib prostate cancer not applicable detail...
Unknown unknown ARV-771 prostate cancer not applicable detail...
Unknown unknown CAB-AXL-ADC prostate cancer not applicable detail...
Unknown unknown ORCA-010 prostate cancer not applicable detail...
BRAF fusion Trametinib prostate cancer no benefit detail...
BRAF G466A Trametinib prostate cancer no benefit detail...
BRAF D594G Trametinib prostate cancer no benefit detail...
Unknown unknown ARV-110 prostate cancer not applicable detail...
Unknown unknown MGC018 prostate cancer not applicable detail...
ATM del Berzosertib prostate cancer sensitive detail...
ATM del Olaparib prostate cancer no benefit detail...
ATM del Rucaparib prostate cancer no benefit detail...
Unknown unknown ZEN-3694 prostate cancer not applicable detail...
Unknown unknown Enzalutamide + ZEN-3694 prostate cancer not applicable detail...
Unknown unknown Atezolizumab + Cabozantinib prostate cancer not applicable detail...
Unknown unknown Capivasertib + Enzalutamide prostate cancer not applicable detail...
Unknown unknown WNY0824 prostate cancer not applicable detail...
Unknown unknown VT-464 prostate cancer no benefit detail...
Unknown unknown Enzalutamide + Pembrolizumab prostate cancer not applicable detail...
Unknown unknown ASG-5ME prostate cancer no benefit detail...
Unknown unknown Enzalutamide + Ipatasertib prostate cancer not applicable detail...
Unknown unknown PX-866 prostate cancer not applicable detail...
Unknown unknown Abiraterone + PX-866 prostate cancer not applicable detail...
Unknown unknown Olaparib + THZ1 prostate cancer not applicable detail...
Unknown unknown LFA102 prostate cancer no benefit detail...
Unknown unknown Mogamulizumab + Tremelimumab prostate cancer not applicable detail...
Unknown unknown Ipilimumab + Nivolumab prostate cancer not applicable detail...
Unknown unknown CC-115 prostate cancer not applicable detail...
Clinical Trial Phase Therapies Title Recruitment Status
NCT00313599 Phase I Lapatinib + Paclitaxel Lapatinib and Paclitaxel in Treating Patients With Advanced Solid Tumors Completed
NCT00670046 Phase II Valproic acid Valproic Acid in Treating Patients With Progressive, Non-Metastatic Prostate Cancer Terminated
NCT00892736 Phase I Veliparib Veliparib in Treating Patients With Malignant Solid Tumors That Did Not Respond to Previous Therapy Completed
NCT00942331 Phase III Bevacizumab + Cisplatin + Gemcitabine Cisplatin + Gemcitabine Gemcitabine Hydrochloride and Cisplatin With or Without Bevacizumab in Treating Patients With Advanced Urinary Tract Cancer Active, not recruiting
NCT01254864 Phase II Abiraterone + Sunitinib Abiraterone + Dasatinib Maximum Androgen Depletion Active, not recruiting
NCT01286987 Phase I Talazoparib Study of BMN 673, a PARP Inhibitor, in Patients With Advanced or Recurrent Solid Tumors Completed
NCT01353625 Phase I CC-115 Study to Assess Safety and Tolerability of Oral CC-115 for Patients With Advanced Solid Tumors, and Hematologic Malignancies. Active, not recruiting
NCT01436968 Phase III Valacyclovir AdV-tk + Valacyclovir Phase 3 Study of ProstAtak Immunotherapy With Standard Radiation Therapy for Localized Prostate Cancer Recruiting
NCT01480154 Phase I Hydroxychloroquine + MK2206 Akt Inhibitor MK2206 and Hydroxychloroquine in Treating Patients With Advanced Solid Tumors, Melanoma, Prostate or Kidney Cancer Active, not recruiting
NCT01517802 Phase III Abiraterone A Study That Provides Long-term Safety Follow-up and Examines Long-term Exposure to Abiraterone Acetate Active, not recruiting
NCT01530984 Phase II Sargramostim Ipilimumab Ipilimumab and GMCSF Immunotherapy for Prostate Cancer Withdrawn
NCT01540526 Phase I Axitinib Pharmacodynamic Study With FLT-PET/CT in Patients With Prostate/Other Solid Malignancies Treated With High Dose Axitinib Completed
NCT01543776 Phase II Abiraterone Food Effect Study of Abiraterone Acetate for Treatment of Patients With Castration-Resistant Prostate Cancer Completed
NCT01553188 Phase II Prednisone Abiraterone Trebananib AMG 386 and Abiraterone for Advanced Prostate Cancer Completed
NCT01576172 Phase II Abiraterone + Prednisone Abiraterone + Prednisone + Veliparib Abiraterone Acetate and Prednisone With or Without Veliparib in Treating Patients With Metastatic Castration-Resistant Prostate Cancer Active, not recruiting
NCT01587703 Phase I Molibresib A Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics, and Clinical Activity of GSK525762 in Subjects With NUT Midline Carcinoma (NMC) and Other Cancers Completed
NCT01607905 Phase I Selinexor Safety Study of the Selective Inhibitor of Nuclear Export (SINE) KPT-330 in Patients With Advanced or Metastatic Solid Tumor Cancer Completed
NCT01620593 Phase II Metformin Castration Compared to Castration Plus Metformin as First Line Treatment for Patients With Advanced Prostate Cancer Completed
NCT01674270 Phase II Bicalutamide Degarelix Degarelix Neo-Adjuvant Radical Prostatectomy Trial Completed
NCT01683994 Phase I Cabozantinib + Docetaxel Cabozantinib Plus Docetaxel and Prednisone for Advanced Prostate Cancer Completed
NCT01685125 Phase II Dasatinib Abiraterone Abiraterone Acetate and Prednisone With or Without Dasatinib in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer Unknown status
NCT01715285 Phase III Abiraterone + Prednisone A Study of Abiraterone Acetate Plus Low-Dose Prednisone Plus Androgen Deprivation Therapy (ADT) Versus ADT Alone in Newly Diagnosed Participants With High-Risk, Metastatic Hormone-Naive Prostate Cancer (mHNPC) Active, not recruiting
NCT01717053 Phase II Leuprolide Abiraterone Prednisone Goserelin Abiraterone, Radiotherapy and Short-Term Androgen Deprivation in Unfavorable Localized Prostate Cancer Active, not recruiting
NCT01730118 Phase I HER2 Vaccine Ad/HER2/Neu Dendritic Cell Cancer Vaccine Testing Completed
NCT01741753 Phase I Abiraterone + Buparlisib + Prednisone BKM120+Abiraterone Acetate for Metastatic CRPC Terminated
NCT01751451 Phase II Abiraterone Degarelix 3-arm Study of Abiraterone Acetate Alone, Abiraterone Acetate Plus Degarelix, a GnRH Antagonist, and Degarelix Alone for Patients With Prostate Cancer With a Rising PSA or a Rising PSA and Nodal Disease Following Definitive Radical Prostatectomy Active, not recruiting
NCT01809691 Phase III Orteronel Bicalutamide S1216, Phase III ADT+TAK-700 vs. ADT+Bicalutamide for Metastatic Prostate Cancer Active, not recruiting
NCT01818986 Phase II Sipuleucel-T Sipuleucel-T and Stereotactic Ablative Body Radiation (SABR) for Metastatic Castrate-resistant Prostate Cancer (mCRPC) Active, not recruiting
NCT01828476 Phase II Hydroxychloroquine Abiraterone + Navitoclax Navitoclax and Abiraterone Acetate With or Without Hydroxychloroquine in Treating Patients With Progressive Metastatic Castrate Refractory Prostate Cancer Terminated
NCT01834651 Phase II Cabozantinib A Phase II Study of Cabozantinib (XL184) Therapy in Castrate Resistant Prostate Cancer (CRPC) With Visceral Metastases Completed
NCT01864096 Phase III Metformin The Metformin Active Surveillance Trial (MAST) Study Recruiting
NCT01867333 Phase II PROSTVAC-F-TRICOM Enzalutamide Enzalutamide With or Without Vaccine Therapy for Advanced Prostate Cancer Active, not recruiting
NCT01875250 Phase II Enzalutamide + PROSTVAC-F-TRICOM + PROSTVAC-V-TRICOM Enzalutamide in Combination With PSA-TRICOM in Patients With Non-Metastatic Castration Sensitive Prostate Cancer Completed
NCT01884285 Phase I AZD8186 Abiraterone + AZD8186 AZD8186 + Vistusertib AZD8186 First Time In Patient Ascending Dose Study Completed
NCT01913106 Phase Ib/II AdV-tk + Valacyclovir HSV-tk + Valacyclovir Therapy in Combination With Brachytherapy for Recurrent Prostate Cancer Recruiting
NCT01920061 Phase I Dacomitinib + Gedatolisib Cisplatin + Gedatolisib Docetaxel + Gedatolisib A Study Of PF-05212384 In Combination With Other Anti-Tumor Agents and in Combination With Cisplatin in Patients With Triple Negative Breast Cancer in an Expansion Arm (TNBC) Completed
NCT01966445 Phase I GSK2849330 Dose Escalation Study to Investigate the Safety, Pharmacokinetics, and Pharmacodynamics of GSK2849330 in Subjects With Advanced Her3-Positive Solid Tumors Completed
NCT01972217 Phase II Prednisone Abiraterone Olaparib Ph II Study to Evaluate Olaparib With Abiraterone in Treating Metastatic Castration Resistant Prostate Cancer Active, not recruiting
NCT01989546 Phase Ib/II Talazoparib Pilot Trial of BMN 673, an Oral PARP Inhibitor, in Patients With Advanced Solid Tumors and Deleterious BRCA Mutations Completed
NCT01990196 Phase II Dasatinib Trametinib Degarelix + Enzalutamide Neoadjuvant Phase 2 Study Comparing the Effects of AR Inhibition With/Without SRC or MEK Inhibition in Prostate Cancer Active, not recruiting
NCT01994590 Phase II Dovitinib Dovitinib (TKI258) and Abiraterone Acetate in Metastatic Castrate-Resistant Prostate Cancer (mCRPC) Terminated
NCT02009449 Phase I Fluorouracil + Leucovorin + Oxaliplatin + Pembrolizumab Pembrolizumab Carboplatin Gemcitabine Docetaxel Pazopanib Capecitabine Paclitaxel Cisplatin Pegilodecakin Nab-paclitaxel A Phase 1 Study of AM0010 in Patients With Advanced Solid Tumors Active, not recruiting
NCT02012296 Phase Ib/II Mifepristone Enzalutamide Enzalutamide and Mifepristone in Treating Patients With Metastatic Hormone Resistant Prostate Cancer Recruiting
NCT02014337 Phase I Eribulin + Mifepristone Mifepristone and Eribulin in Patients With Metastatic Triple Negative Breast Cancer or Other Specified Solid Tumors Completed
NCT02020070 Phase II Ipilimumab Degarelix Combining Ipilimumab, Degarelix, and Radical Prostatectomy in Men With Newly Diagnosed Metastatic Castration Sensitive Prostate Cancer or Ipilimumab and Degarelix in Men With Biochemically Recurrent Castration Sensitive Prostate Cancer After Radical Prostatectomy Active, not recruiting
NCT02028988 Phase II Enzalutamide Enzalutamide + External Beam Rt For Prostate Active, not recruiting
NCT02043665 Phase I Coxsackievirus A21 Systemic Treatment Of Resistant Metastatic Disease Employing CVA21 and Pembrolizumab in Non-small Cell Lung Cancer and Bladder Cancer (STORM/ KEYNOTE-200) (STORM) Completed
NCT02059213 Phase II Goserelin Palbociclib Bicalutamide Leuprolide A Phase II Study of Androgen Deprivation Therapy With or Without PD 0332991 in RB-Positive Metastatic Prostate Cancer Completed
NCT02091531 Phase II Sapanisertib Dual mTOR Inhibitor MLN0128 in Advanced Castration-Resistant Prostate Cancer (CRPC) Patients Completed
NCT02115828 Phase I Vismodegib A Study of Vismodegib in Men With Metastatic CRPC With Accessible Metastatic Lesions for Tumor Biopsy Completed
NCT02159950 Phase II Sipuleucel-T Tasquinimod Sipuleucel-T With or Without Tasquinimod in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer Completed
NCT02218606 Phase II Cabazitaxel Abiraterone + Prednisone Multicenter Trial of Abiraterone Acetate With or Without Cabazitaxel in Treatment of Metastatic Castration Resistant Prostate Cancer Active, not recruiting
NCT02234921 Phase I Cyclophosphamide Pilot Study of DRibble Vaccine for Prostate Cancer Patients Completed
NCT02259114 Phase I Birabresib A Phase IB Trial With OTX015, a Small Molecule Inhibitor of the Bromodomain and Extra-Terminal (BET) Proteins, in Patients With Selected Advanced Solid Tumors Completed
NCT02265536 Phase I LY3022855 A Study of LY3022855 In Participants With Breast or Prostate Cancer Completed
NCT02278185 Phase II Goserelin Degarelix Histrelin acetate Triptorelin Leuprolide Enzalutamide Enzalutamide Versus Standard Androgen Deprivation Therapy for the Treatment Hormone Sensitive Prostate Cancer Active, not recruiting
NCT02279862 Phase II Ipilimumab Safety and Efficacy Study of Ipilimumab 3 mg/kg Versus Ipilimumab 10 mg/kg in Subjects With Metastatic Castration Resistant Prostate Cancer Who Are Chemotherapy Naive Completed
NCT02312557 Phase II Enzalutamide + Pembrolizumab Pembrolizumab in Treating Patients With Metastatic Castration Resistant Prostate Cancer Previously Treated With Enzalutamide Active, not recruiting
NCT02325557 Phase Ib/II Pembrolizumab ADXS31-142 ADXS31-142 Alone and in Combination With Pembrolizumab (MK-3475) in Patients With Prostate Cancer - KEYNOTE-046 Active, not recruiting
NCT02339168 Phase I Enzalutamide + Metformin Enzalutamide and Metformin Hydrochloride in Treating Patients With Hormone-Resistant Prostate Cancer Active, not recruiting
NCT02366494 Phase I Leuprolide Goserelin Triptorelin Bicalutamide Docetaxel Micro RNAs to Predict Response to Androgen Deprivation Therapy Recruiting
NCT02403505 Phase II Enzalutamide Abiraterone Prednisone Degarelix Discovery Stage Clinical Study About Oncology Drugs and Single Nucleotide Polymorphisms Active, not recruiting
NCT02420652 Phase II Metformin Metformin Hydrochloride and Aspirin in Treating Patients With Hormone-Dependent Prostate Cancer That Has Progressed After Surgery or Radiation Therapy Terminated
NCT02429193 Phase II Enzalutamide Abiraterone + Prednisone Biomarkers of Androgen Response and Resistance In Evolution During a Rising PSA (BARRIER-P) Completed
NCT02430480 Phase II Goserelin Using Multiparametric MRI to Evaluate Intraprostatic Tumor Responses and Androgen Resistance Patterns in Newly Diagnosed Prostate Cancer Active, not recruiting
NCT02438007 Phase III Galeterone Enzalutamide A Study of Galeterone Compared to Enzalutamide In Men Expressing Androgen Receptor Splice Variant-7 mRNA (AR-V7) Metastatic CRPC Terminated
NCT02452008 Phase II Galunisertib Enzalutamide Study of TGF-Beta Receptor Inhibitor LY2157299 and Enzalutamide in Metastatic Castration-resistant Prostate Cancer Recruiting
NCT02489357 Phase I Degarelix Pembrolizumab Pembrolizumab and Cryosurgery in Treating Patients With Newly Diagnosed, Oligo-metastatic Prostate Cancer Completed
NCT02494921 Phase Ib/II Docetaxel + Filgrastim + Prednisone + Ribociclib LEE011 (Ribociclib) in Combination With Docetaxel Plus Prednisone in mCRPC Active, not recruiting
NCT02507570 Phase II Enzalutamide Radium Ra 223 dichloride Open Label Phase Two Study of Enzalutamide With Concurrent Administration of Radium Ra 223 Dichloride in Castration-Resistant (Hormone-Refractory) Prostate Cancer Subjects With Symptomatic Bone Metastasis Completed
NCT02522715 Phase Ib/II Cabazitaxel + Enzalutamide Prednisone Enzalutamide and Cabazitaxel in Treating Patients With Metastatic, Hormone-Resistant Prostate Cancer Active, not recruiting
NCT02531516 Phase III Abiraterone + Apalutamide + Prednisone Bicalutamide An Efficacy and Safety Study of JNJ-56021927 (ARN-509) in High-risk Prostate Cancer Subjects Receiving Primary Radiation Therapy Active, not recruiting
NCT02555189 Phase Ib/II Ribociclib Enzalutamide Enzalutamide With and Without Ribociclib for Metastatic, Castrate-Resistant, Chemotherapy-Naive Prostate Cancer That Retains RB Expression Recruiting
NCT02566772 Phase I TAS3681 Study of TAS3681 in Metastatic Castration Resistant Prostate Cancer Recruiting
NCT02575781 Phase I SAR428926 A Study of SAR428926 in Patients With Advanced Solid Tumors Completed
NCT02594072 Phase I Goserelin Androgen Suppression With Stereotactic Body or External Beam Radiation Therapy (ASSERT) (ASSERT) Recruiting
NCT02607228 Phase Ib/II Enzalutamide Exemestane + GS-5829 Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of GS-5829 as a Single Agent and In Combination With Enzalutamide in Participants With Metastatic Castrate-Resistant Prostate Cancer Completed
NCT02614859 Phase II Bicalutamide Metformin Bicalutamide With or Without Metformin for Biochemical Recurrence in Overweight or Obese Prostate Cancer Patients Active, not recruiting
NCT02616185 Phase I PF-06755990 + PF-06755992 + Sunitinib + Tremelimumab A Phase 1 Study To Evaluate Escalating Doses Of A Vaccine-Based Immunotherapy Regimen For Prostate Cancer (PrCa VBIR) Recruiting
NCT02628535 Phase I MGD009 Safety Study of MGD009 in B7-H3-expressing Tumors Terminated
NCT02660034 Phase I Pamiparib + Tislelizumab The Safety, Pharmacokinetics and Antitumor Activity of BGB-A317 in Combination With BGB-290 in Participants With Advanced Solid Tumors Active, not recruiting
NCT02663908 Phase III Degarelix Leuprolide A Trial Comparing Cardiovascular Safety of Degarelix Versus Leuprolide in Patients With Advanced Prostate Cancer and Cardiovascular Disease Active, not recruiting
NCT02698176 Phase I Birabresib A Dose Exploration Study With MK-8628 in Participants With Selected Advanced Solid Tumors (MK-8628-006) Terminated
NCT02705469 Phase I ZEN-3694 A Study of ZEN003694 in Patients With Metastatic Castration-Resistant Prostate Cancer Completed
NCT02711956 Phase I Enzalutamide + ZEN-3694 A Study of ZEN003694 in Combination With Enzalutamide in Patients With Metastatic Castration-Resistant Prostate Cancer Active, not recruiting
NCT02721433 FDA approved Denosumab + pamidronate + Zoledronic acid 4-weekly Versus 12-weekly Administration of Bone-targeted Agents in Patients With Bone Metastases (REaCT-BTA) Active, not recruiting
NCT02744287 Phase Ib/II BPX-601 + Rimiducid Use of Ligand-Inducible Autologous T Cells Engineered to Target PSCA on Tumor Cells in Selected Advanced Solid Tumors Recruiting
NCT02766478 Phase II Genistein Genistein Supplementation to Mitigate Cardiometabolic Dysfunction in Patients Undergoing Androgen Deprivation Therapy for Prostate Cancer Suspended
NCT02796898 Phase Ib/II SM88 Study of the Efficacy, Safety, and Pharmacokinetics of SM88 in Patients With Prostate Cancer Completed
NCT02807805 Phase II Abiraterone + Niclosamide + Prednisone Abiraterone Acetate, Niclosamide, and Prednisone in Treating Patients With Hormone-Resistant Prostate Cancer Recruiting
NCT02833883 Phase I CC-115 + Enzalutamide Use of an Experimental Drug, CC-115, With Enzalutamide in Men With Castration-Resistant Prostate Cancer Active, not recruiting
NCT02854436 Phase II Niraparib An Efficacy and Safety Study of Niraparib in Men With Metastatic Castration-Resistant Prostate Cancer and DNA-Repair Anomalies Active, not recruiting
NCT02881242 Phase II Trametinib Trametinib in Treating Patients With Progressive Metastatic Hormone-Resistant Prostate Cancer Active, not recruiting
NCT02887976 Phase III Abiraterone + Methylprednisolone Extension of SoluMatrix TM Abiraterone Acetate in Patients Who Completed Study Number CHL-AA-201 Completed
NCT02900651 Phase Ib/II MAK683 Safety and Efficacy of MAK683 in Adult Patients With Advanced Malignancies Recruiting
NCT02924766 Phase I Apalutamide + Niraparib A Safety and Pharmacokinetics Study of Niraparib Plus Apalutamide in Men With Metastatic Castration-Resistant Prostate Cancer (BEDIVERE) Completed
NCT02933255 Phase Ib/II Ipilimumab + PROSTVAC-F-TRICOM + PROSTVAC-V-TRICOM Ipilimumab + Nivolumab + PROSTVAC-F-TRICOM + PROSTVAC-V-TRICOM Nivolumab + PROSTVAC-F-TRICOM + PROSTVAC-V-TRICOM PROSTVAC in Combination With Nivolumab and/or Ipilimumab in Men With Prostate Cancer Recruiting
NCT02935205 Phase Ib/II Enzalutamide + Indomethacin Enzalutamide and Indomethacin in Treating Patients With Recurrent or Metastatic Hormone-Resistant Prostate Cancer Recruiting
NCT02947165 Phase I NIS793 + Spartalizumab NIS793 Phase I/Ib Study of NIS793 in Combination With PDR001 in Patients With Advanced Malignancies. Recruiting
NCT02950064 Phase I BTP-114 A Study to Determine the Safety of BTP-114 for Treatment in Patients With Advanced Solid Tumors With BRCA Mutations Active, not recruiting
NCT02960022 Phase II Abiraterone + Enzalutamide + Prednisone Enzalutamide A Study for Subjects With Prostate Cancer Who Previously Participated in an Enzalutamide Clinical Study Recruiting
NCT02966587 Phase II Durvalumab Durvalumab in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer Withdrawn
NCT02985957 Phase II Ipilimumab + Nivolumab A Study to Evaluate Preliminary Safety and Efficacy of Nivolumab Plus Ipilimumab in Men With Metastatic Castration-Resistant Prostate Cancer Recruiting
NCT02987543 Phase III Olaparib Enzalutamide Abiraterone Study of Olaparib (Lynparza) Versus Enzalutamide or Abiraterone Acetate in Men With Metastatic Castration-Resistant Prostate Cancer (PROfound Study) Active, not recruiting
NCT03016741 FDA approved Enzalutamide Abiraterone + Prednisone Cognitive Effects of Androgen Receptor Directed Therapies for Advanced Prostate Cancer Recruiting
NCT03067051 Phase I Verteporfin Clinical Study to Assess the Safety and Adequacy of Effectiveness of the SpectraCure P18 System Recruiting
NCT03089203 Phase I CART-PSMA-TGF-beta RDN Cyclophosphamide + Fludarabine CART-PSMA-TGF-beta RDN Cells for Castrate-Resistant Prostate Cancer Recruiting
NCT03098160 Phase I Evofosfamide + Ipilimumab Immunotherapy Study of Evofosfamide in Combination With Ipilimumab Unknown status
NCT03102606 Phase II Plinabulin Pegfilgrastim Plinabulin vs. Pegfilgrastim in Patients With Solid Tumors Receiving Docetaxel Myelosuppressive Chemotherapy (Protective-1) Active, not recruiting
NCT03120832 Phase I PAN-301-1 Phase 1 Trial of PAN-301-1 in Cancer Patients Completed
NCT03123978 Phase I Enzalutamide + Niclosamide Enzalutamide and Niclosamide in Treating Patients With Recurrent or Metastatic Castration-Resistant Prostate Cancer Recruiting
NCT03141671 Phase II Bicalutamide + Gonadorelin Abiraterone + Apalutamide + Gonadorelin + Prednisone Randomized Phase II Study of Salvage XRT + ADT +/- Abiraterone and Apalutamide for Rising PSA After RP (FORMULA-509) Active, not recruiting
NCT03150810 Phase Ib/II Pamiparib + Temozolomide Study to Assess Safety, Tolerability and Clinical Activity of BGB-290 in Combination With Temozolomide (TMZ) in Participants With Locally Advanced or Metastatic Solid Tumors Recruiting
NCT03179410 Phase II Avelumab PD-L1 Inhibition as ChecKpoint Immunotherapy for NeuroEndocrine Phenotype Prostate Cancer (PICK-NEPC) Active, not recruiting
NCT03188965 Phase I BAY1895344 First-in-human Study of ATR Inhibitor BAY1895344 in Patients With Advanced Solid Tumors and Lymphomas Recruiting
NCT03199586 Phase I NP-G2-044 Phase 1 Clinical Trial of Metastasis Inhibitor NP-G2-044 in Patients With Advanced or Metastatic Solid Tumors (Including Lymphoma) Recruiting
NCT03217747 Phase Ib/II Avelumab + PF-04518600 + Utomilumab Avelumab + Utomilumab Avelumab + PF-04518600 Avelumab, Utomilumab, Anti-OX40 Antibody PF-04518600, and Radiation Therapy in Treating Patients With Advanced Malignancies Recruiting
NCT03311555 Phase II Apalutamide + Docetaxel A Salvage Trial of AR Inhibition With ADT and Apalutamide With Radiation Therapy Followed by Docetaxel in Men With PSA Recurrent Prostate Cancer After Radical Prostatectomy (STARTAR) Active, not recruiting
NCT03315871 Phase II CV301 + M7824 + PROSTVAC-F-TRICOM + PROSTVAC-V-TRICOM Combination Immunotherapy in Biochemically Recurrent Prostate Cancer Recruiting
NCT03325127 Phase I Abiraterone + Enzalutamide + Radium Ra 223 dichloride Outcomes of mCRPC Patients Treated With Ra-223 Concomitant With Abiraterone or Enzalutamide- A Chart Review Study Withdrawn
NCT03330405 Phase II Avelumab + Talazoparib Javelin Parp Medley: Avelumab Plus Talazoparib In Locally Advanced Or Metastatic Solid Tumors Active, not recruiting
NCT03333616 Phase II Ipilimumab + Nivolumab Nivolumab Combined With Ipilimumab for Patients With Advanced Rare Genitourinary Tumors Recruiting
NCT03344211 Phase II Enzalutamide + Radium Ra 223 dichloride Enzalutamide Enzalutamide With or Without Radium Ra 223 Dichloride in Patients With Metastatic, Castration-Resistant Prostate Cancer Recruiting
NCT03358563 Phase I Bicalutamide + Degarelix + Docetaxel Pilot Trial of Chemohormonal Therapy Followed by Prostatectomy in High Risk Prostate Cancer Suspended
NCT03360006 Phase I ABBV-744 A Study Evaluating the Safety and Pharmacokinetics of ABBV-744 in Subjects With Advanced Prostate Cancer (CRPC) and Relapsed/Refractory Acute Myeloid Leukemia (AML) Cancer Recruiting
NCT03363776 Phase Ib/II BMS-986277 BMS-986277 + Nivolumab An Immuno-Therapy Study of Experimental Medication BMS-986277 Given Alone and in Combination With Nivolumab in Epithelial Cancers Active, not recruiting
NCT03363893 Phase Ib/II ICEC0942 Fulvestrant + ICEC0942 Modular Study to Evaluate CT7001 Alone in Cancer Patients With Advanced Malignancies Recruiting
NCT03367819 Phase Ib/II Isatuximab Cemiplimab + Isatuximab Isatuximab in Combination With REGN2810 in Patients With Advanced Malignancies Active, not recruiting
NCT03409458 Phase Ib/II Avelumab + Imifoplatin A Dose Escalation and Confirmation Study of PT-112 in Advanced Solid Tumors in Combination With Avelumab (PAVE-1) Unknown status
NCT03418324 Phase II Abiraterone + Carotuximab Carotuximab + Enzalutamide Study of TRC105 With Abiraterone and With Enzalutamide in Prostate Cancer Patients Progressing on Therapy Completed
NCT03450109 Phase I LY01005 Goserelin A Study to Assess LY01005 Versus Goserelin Comparator (ZOLADEX) in Patients With Prostate Cancer Completed
NCT03454451 Phase I CPI-006 CPI-006 + Pembrolizumab CPI-006 + CPI-444 CPI-006 Alone and in Combination With Ciforadenant and With Pembrolizumab for Patients With Advanced Cancers Recruiting
NCT03460977 Phase I PF-06821497 PF-06821497 Treatment Of Relapsed/Refractory SCLC, Castration Resistant Prostate Cancer, and Follicular Lymphoma Recruiting
NCT03473925 Phase II Navarixin + Pembrolizumab Efficacy and Safety Study of Navarixin (MK-7123) in Combination With Pembrolizumab (MK-3475) in Adults With Selected Advanced/Metastatic Solid Tumors (MK-7123-034) Active, not recruiting
NCT03477864 Phase I Ipilimumab Cemiplimab + Ipilimumab Cemiplimab Stereotactic Body Radiation Therapy With REGN2810 and/or Ipilimumab Before Surgery in Treating Participants With Progressive Advanced or Oligometastatic Prostate Cancer Withdrawn
NCT03478904 Phase I Enzalutamide Study to Compare Capsule and Liquid Formulations of Enzalutamide After Single Dose Administration Under Fasting Conditions in Prostate Cancer Recruiting
NCT03481816 Phase I ETBX-051 + ETBX-061 + ETBX-071 Treatment of Castration Resistant Prostate Cancer Using Multi-Targeted Recombinant Ad5 PSA/MUC1/Brachyury Based Immunotherapy Vaccines Active, not recruiting
NCT03493945 Phase Ib/II ALT-803 + Epacadostat + FPV-Brachyury + M7824 + MVA-BN-Brachyury FPV-Brachyury + M7824 + MVA-BN-Brachyury ALT-803 + FPV-Brachyury + M7824 + MVA-BN-Brachyury ALT-803 + M7824 Phase I/II Study of Immunotherapy Combination BN-Brachyury Vaccine, M7824, ALT-803 and Epacadostat (QuEST1). Recruiting
NCT03507608 Phase I Flutamide Assessing Induction of Double Strand Breaks With Androgen Receptor Partial Agonist in Patients on Androgen Suppression Recruiting
NCT03511664 Phase III 177Lu-PSMA-617 Study of 177Lu-PSMA-617 In Metastatic Castrate-Resistant Prostate Cancer (VISION) Active, not recruiting
NCT03517969 Phase II Carboplatin + Docetaxel Berzosertib + Carboplatin ATR Kinase Inhibitor VX-970 and Carboplatin With or Without Docetaxel in Treating Participants With Metastatic Castration-Resistant Prostate Cancer Suspended
NCT03531827 Phase II CRLX101 + Enzalutamide Combining CRLX101, a Nanoparticle Camptothecin, With Enzalutamide in People With Progressive Metastatic Castration Resistant Prostate Cancer Following Prior Enzalutamide Treatment Recruiting
NCT03543189 Phase Ib/II Nivolumab Combination of Nivolumab Immunotherapy With Radiation Therapy and Androgen Deprivation Therapy Recruiting
NCT03565445 Phase I ASP1948 + Nivolumab ASP1948 A Study of ASP1948, Targeting an Immune Modulatory Receptor, in Subjects With Advanced Solid Tumors Recruiting
NCT03568539 Phase Ib/II Sintilimab IBI308 in Subjects With Advanced/Metastatic Solid Malignancies Active, not recruiting
NCT03572478 Phase Ib/II Nivolumab + Rucaparib Nivolumab Rucaparib Rucaparib and Nivolumab in Patients With Prostate or Endometrial Cancer Active, not recruiting
NCT03575819 Phase I FOR46 A Phase 1 Study of FOR46 in Patients With Metastatic Castration-Resistant Prostate Cancer (mCRPC) Recruiting
NCT03592264 Phase Ib/II OBI-3424 This Study is to Evaluate OBI-3424 Safe and Effective Treatment Dose in Subjects With Hepatocellular Carcinoma or Castrate Resistant Prostate Cancer Recruiting
NCT03674814 Phase I Enzalutamide + Relacorilant Study of Drug 1 (Enzalutamide) Plus Drug 2 (Relacorilant) for Patients With Prostate Cancer Recruiting
NCT03685591 Phase I PF-06952229 Enzalutamide + PF-06952229 Letrozole + Palbociclib + PF-06952229 PF-06952229 Treatment in Adult Patients With Advanced Solid Tumors Recruiting
NCT03689699 Phase II BMS-986253 + Degarelix + Nivolumab Degarelix + Nivolumab Nivolumab and BMS-986253 for Hormone-Sensitive Prostate Cancer (MAGIC-8) Recruiting
NCT03709550 Phase Ib/II Decitabine + Enzalutamide Enzalutamide and Decitabine in Treating Patients With Metastatic Castration Resistant Prostate Cancer Not yet recruiting
NCT03751436 Phase Ib/II Enzalutamide + Venetoclax Enzalutamide With Venetoclax in Treating Patients With Metastatic Castration Resistant Prostate Cancer Recruiting
NCT03761225 Phase III Docetaxel + Prednisone Docetaxel + Masitinib + Prednisone Masitinib Plus Docetaxel in Metastatic Castration-resistant Prostate Cancer Recruiting
NCT03777982 Phase III Abiraterone + Apalutamide + Prednisone A Randomized Phase III Study - Conventional ADT w/ or w/Out Abiraterone Acetate + Prednisone and Apalutamide Following a Detectable PSA After Radiation and ADT Recruiting
NCT03784677 Phase I SOR-C13 SOR-C13 in Treating Patients With Advanced Refractory Solid Tumors Recruiting
NCT03792841 Phase I AMG 160 + Pembrolizumab AMG 160 Safety, Tolerability, Pharmacokinetics, and Efficacy of AMG 160 in Subjects With mCRPC Recruiting
NCT03799003 Phase I ASP1951 A Study of ASP1951 in Subjects With Advanced Solid Tumors Recruiting
NCT03810105 Phase II Durvalumab + Olaparib A Study of Olaparib and Durvalumab in Prostate Cancer Recruiting
NCT03811652 Phase I MEDI7247 A Multiple Ascending Dose Study of MEDI7247 in Advanced or Metastatic Solid Tumors Completed
NCT03835533 Phase I CDX-301 + INO-5151 + Nivolumab CDX-301 + Nivolumab + Poly ICLC Nivolumab + NKTR-214 Platform Study for Prostate Researching Translational Endpoints Correlated to Response to Inform Use of Novel Combinations (PORTER) Recruiting
NCT03860987 Phase II Abiraterone + Enzalutamide + Goserelin + Prednisone Neoadjuvant Androgen Deprivation Therapy Combined With Enzalutamide and Abiraterone Using Multiparametric MRI and 18FDCFPyL PET/CT in Newly Diagnosed Prostate Cancer Recruiting
NCT03873805 Phase I Cyclophosphamide + Fludarabine Anti-PSCA(dCH2)BBz-CAR T-cells PSCA-CAR T Cells in Treating Patients With PSCA+ Metastatic Castration Resistant Prostate Cancer Recruiting
NCT03878524 Phase I Oxaliplatin Palbociclib Vemurafenib Sirolimus Tretinoin Celecoxib Ipilimumab Ruxolitinib Dasatinib Abiraterone Idelalisib Trametinib Imatinib Erlotinib Carboplatin Olaparib Panobinostat Bortezomib Afatinib Fluorouracil Vorinostat Pembrolizumab Leucovorin Enzalutamide Ponatinib Nivolumab Everolimus Sunitinib Cabazitaxel Cabozantinib Lenvatinib Pertuzumab Sorafenib Venetoclax Bevacizumab A Personalized Medicine Study for Patients With Advanced Cancer of the Breast, Prostate, Pancreas or Those With Refractory Acute Myelogenous Leukemia (SMMART) Recruiting
NCT03899467 Phase II Proxalutamide the Safety and Tolerability of Proxalutamide (GT0918) in Subjects With Metastatic Castrate Resistant Prostate Cancer Recruiting
NCT03934840 Phase II Abiraterone + Cabazitaxel + Carboplatin + Prednisone Phase 2 of Carbo, Taxel and Abi in Metastatic Castration Prostate Cancer Recruiting
NCT03936959 Phase I LY3434172 A Study of LY3434172, a PD-1 and PD-L1 Bispecific Antibody, in Advanced Cancer Active, not recruiting
NCT03951831 Phase II Cemiplimab + Degarelix + Docetaxel + Leuprolide REGN2810 Followed by Chemoimmunotherapy for Newly Metastatic Hormone-sensitive Prostate Cancer Recruiting
NCT03970382 Phase I NeoTCR-P1 T-cells + Nivolumab NeoTCR-P1 T-cells A Study of Gene Edited Autologous Neoantigen Targeted TCR T Cells With or Without Anti-PD-1 in Patients With Solid Tumors Recruiting
NCT04009967 Phase II Pembrolizumab Biomarkers for Neoadjuvant Pembrolizumab in Non-Metastatic Prostate Cancer Positive by 18FDG-PET Scanning (PICT-01) Recruiting
NCT04019964 Phase II Nivolumab Nivolumab in Biochemically Recurrent dMMR Prostate Cancer Recruiting
NCT04030559 Phase II Niraparib Niraparib Before Surgery in Treating Patients With High Risk Localized Prostate Cancer and DNA Damage Response Defects Recruiting
NCT04038502 Phase II Carboplatin Docetaxel BRcA Deficient Prostate Cancer Treated With Carboplatin or Docetaxel Suspended
NCT04052204 Phase II Avelumab + NKTR-214 Avelumab + NKTR-214 + Talazoparib Avelumab + Enzalutamide + NKTR-214 Avelumab With Bempegaldesleukin With or Without Talazoparib or Enzalutamide in Advanced or Metastatic Solid Tumors Active, not recruiting
NCT04060342 Phase Ib/II GB1275 GB1275 + Pembrolizumab GB1275 + Gemcitabine + Nab-paclitaxel GB1275 Monotherapy and in Combination With an Anti-PD1 Antibody in Patients With Specified Advanced Solid Tumors or in Combination With Standard of Care in Patients With Metastatic Pancreatic Adenocarcinoma Recruiting
NCT04068896 Phase I NGM120 Study of NGM120 in Subjects With Advanced Solid Tumors and Pancreatic Cancer Using Combination Therapy Recruiting
NCT04071236 Phase Ib/II MSC2490484A + Radium Ra 223 dichloride Radium Ra 223 dichloride Avelumab + MSC2490484A + Radium Ra 223 dichloride Radiation Medication (Radium-223 Dichloride) Versus Radium-223 Dichloride Plus Radiation Enhancing Medication (M3814) Versus Radium-223 Dichloride Plus M3814 Plus Avelumab (a Type of Immunotherapy) for Advanced Prostate Cancer Not Responsive to Hormonal Therapy Recruiting
NCT04087174 Phase I Abiraterone + Capivasertib Capivasertib + Enzalutamide A Multi-centre Study to Assess the Safety, Tolerability, and Pharmacokinetics of Capivasertib (AZD5363) in Combination With Novel Agents in Patients With Metastatic Prostate Cancer Recruiting
NCT04089553 Phase II AZD4635 + Durvalumab AZD4635 + Oleclumab An Open-label, Phase II Study of AZD4635 in Patients With Prostate Cancer Recruiting
NCT04095273 Phase I BAY1895344 + Pembrolizumab Study to Test How Well Patients With Advanced Solid Tumors Respond to Treatment With the ATR Inhibitor BAY1895344 in Combination With Pembrolizumab, to Find the Optimal Dose for Patients, How the Drug is Tolerated and the Way the Body Absorbs, Distributes and Discharges the Drug Recruiting
NCT04134312 Phase I MVA-BN-Brachyury A Phase 1 Open Label Trial of Intravenous Administration of MVA-BN-Brachyury Vaccine in Patients With Advanced Cancer Recruiting
NCT04143789 Phase Ib/II AP-002 Evaluation of AP-002 in Patients With Solid Tumors Recruiting
NCT04145375 Phase Ib/II Enzalutamide + ZEN-3694 Continuation Protocol for ZEN003694 in Patients Experiencing Clinical Benefit While Enrolled in a ZEN003694 Protocol Enrolling by invitation
NCT04145622 Phase Ib/II DS-7300a Study of DS-7300a in Participants With Advanced Solid Malignant Tumors Recruiting
NCT04148937 Phase I LY3475070 LY3475070 + Pembrolizumab A Study of the CD73 Inhibitor LY3475070 Alone or in Combination With Pembrolizumab in Participants With Advanced Cancer Recruiting
NCT04157517 Phase I TAK-573 A Safety, Tolerability, Pharmacokinetics (PK), and Pharmacodynamics Study Recruiting
NCT04159896 Phase II CEP-11981 + Nivolumab ESK981 and Nivolumab for the Treatment of Metastatic Castration Resistant Prostate Cancer Not yet recruiting
NCT04182516 Phase I NMS-03305293 Study of NMS-03305293 in Pts With Selected Advanced/Metastatic Solid Tumors Recruiting
NCT04207255 Phase II ABC294640 + Enzalutamide ABC294640 + Abiraterone Addition of Opaganib to Androgen Antagonists in Patients With mCRPC Recruiting
NCT04221542 Phase I AMG 509 + Dexamethasone Study of AMG 509 in Subjects With Metastatic Castration-Resistant Prostate Cancer Recruiting
NCT04249947 Phase I P-PSMA-101 CAR-T cells Rimiducid P-PSMA-101 CAR-T Cells in the Treatment of Subjects With Metastatic Castration-Resistant Prostate Cancer (mCRPC) Suspended
NCT04250597 Phase I GNX102 Study of GNX102 in Patients With Advanced Solid Tumors Recruiting
NCT04253262 Phase Ib/II Copanlisib + Rucaparib A Study of Copanlisib Combined With Rucaparib in Patients With Metastatic Castration-resistant Prostate Cancer Recruiting
NCT04267887 Phase II Abiraterone + Apalutamide + Prednisone Apalutamide, Abiraterone Acetate, and Prednisone for the Treatment of Metastatic High Risk Castration Sensitive Prostate Cancer Recruiting
NCT04337099 Expanded access Tempol A Single Patient Compassionate Use of MBM-02 (Tempol) for the Treatment of Prostate Cancer Available
NCT04337580 Phase II Cabazitaxel + Omeprazole Docetaxel + Omeprazole Fatty Acid Synthase Inhibition in Castration Refractory Prostate Cancer (FASN) Not yet recruiting
NCT04381832 Phase Ib/II AB928 + Enzalutamide + GLS-010 AB928 + Docetaxel + GLS-010 AB680 + AB928 + GLS-010 AB680 + AB928 Enzalutamide Docetaxel AB928 + GLS-010 Adenosine Receptor Antagonist Combination Therapy for Metastatic Castrate Resistant Prostate Cancer (ARC-6) Recruiting
NCT04408924 Phase II Abemaciclib Abemaciclib (LY2835219) in Men With Heavily Treated Metastatic Castration-Resistant Prostate Cancer (CYCLONE 1) Not yet recruiting
NCT04421222 Phase I EPI-7386 Oral EPI-7386 in Patients With Metastatic Castration-Resistant Prostate Cancer (EPI-7386) Recruiting
NCT04477512 Phase I Abiraterone + Cabozantinib + Nivolumab + Prednisone Cabozantinib and Abiraterone With Checkpoint Inhibitor Immunotherapy in Metastatic Hormone Sensitive Prostate Cancer (CABIOS Trial) Not yet recruiting